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Introduction:The purpose of this study is to analyze and validate the 
prognostic impact of the new lung adenocarcinoma (ADC) classifica-
tion proposed by the International Association for the Study of Lung 
Cancer, American Thoracic Society, and European Respiratory Society 
and invasive tumor size in stage I lung ADC of Japanese patients.
Methods:We reclassified 191 stage I ADCs according to the new 
classification. The percentage of each histological subtype and the 
predominant type were determined. In addition, both total tumor size 
and invasive tumor size were examined. The relationship between 
these results and clinicopathological backgrounds was investigated 
statistically.
Results:The 5-year disease-free survival (DFS) of adenocarci-
noma in situ and minimally invasive adenocarcinoma was 100%; 
lepidic-predominant ADCs, 94.9%; papillary-predominant ADCs, 
85.4%; acinar-predominant ADCs, 89.7%; and solid-predominant 
ADCs, 54%. The predominant growth pattern was significantly cor-
related with DFS (p < 0.001, overall). With regard to tumor size, 
total tumor size was not correlated with DFS (p = 0.475, overall), 
however, invasive tumor size was significantly correlated with DFS 
(≤0.5 cm/ > 0.5cm, ≤1cm/ >1 cm, ≤2 cm/>2 cm, ≤3 cm/ >3cm, 
100%/91.5%/85.9%/80.8%/66.7%% in 5-year DFS) (p = 0.006, 
overall). A multivariate analysis showed solid-predominant and 
invasive tumor size were independent predictors of increased risk of 
recurrence (solid versus nonsolid: hazard ratio = 4.08, 95% confi-
dence interval:1.59–10.5, p = 0.003; invasive tumor size: hazard ratio 
= 2.04, 95% confidence interval:1.14–3.63, p = 0.016).
Conclusion:The new International Association for the Study of 
Lung Cancer, American Thoracic Society, and European Respiratory 
Society ADC classification and invasive tumor size are very useful 
predictors of recurrence of stage I ADCs in Japanese patients.
Key Words: Lung adenocarcinoma, Adenocarcinoma in situ, 
Minimally invasive adenocarcinoma, Solid-predominant adenocar-
cinoma, Prognosis.
(J Thorac Oncol. 2013;8: 612–618)
Lung cancer is now a major cause of death in developed countries.1 Among the histological subtypes of lung can-
cer, lung adenocarcinoma (ADC) is the most common, with 
an increasing incidence rate.2 Despite several improvements 
in treatment, the all-stage 5-year survival rate of lung cancer 
is only 15%.1,3 Tumor, node, metastasis (TNM) stage is the 
most important factor to predict the prognosis in lung can-
cer, including ADC.4 The 5-year overall survival for stage I 
patients approaches 67%. However, even with complete resec-
tion by lymph node dissection, approximately 30% to 40% 
of the patients will die of recurrent disease.3,5 Therefore, it is 
important and necessary to identify early-stage patients with 
high risk for recurrence; such identification will be useful in 
determining more careful follow-up and/or additional therapy. 
Histopathological study is the cheapest method of investigat-
ing tumor behavior in comparison with molecular study. The 
international multidisciplinary panel of lung cancer experts, 
including medical oncologists, respiratory physicians, pathol-
ogists, surgeons, molecular biologists, and radiologists, was 
formed in 2008, sponsored by the International Association 
for the Study of Lung Cancer (IASLC), American Thoracic 
Society (ATS), and European Respiratory Society (ERS). 
The result of this collaboration is a new ADC classifica-
tion system called the new IASLC/ATS/ERS International 
Multidisciplinary Lung Adenocarcinoma Classification, 
which was presented in 2009 and published in 2011.6 The 
prognostic impact of this classification has been reported by 
several authors.7–9 In addition, in relation with this classifica-
tion, Yoshizawa et al.7 proposed that invasive tumor size rather 
than total tumor size might be predictive of patient survival.
In this study, we reviewed and reclassified stage I ADCs 
according to the new IASLC/ATS/ERS ADC classification, 
measured invasive tumor size, and investigated its correlation 
with the clinicopathological background of patients, including 
patient outcome.
PATIENTS AND METHODS
Patients and Tissues
A retrospective review of a prospectively maintained 
surgical database was performed to identify patients who 
underwent primary lung cancer resection, with curative intent, 
from 1998 to 2007. All the patients had a histopathologic 
diagnosis of stage I ADC defined as a malignant epithelial 
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neoplasm, with glandular differentiation or mucin produc-
tion and histopathologic patterns, including acinar, papillary, 
bronchioloalveolar carcinoma, or solid with mucin or mixed 
types of these patterns according to the 2004 World Health 
Organization classification,10 and the 7th edition of the TNM 
Classification of the Union for International Cancer Control.11 
Written informed consent was obtained from each patient and 
the study design has been approved by an institutional ethics 
review board. A total of 191 patients with stage I ADC were 
examined.
Histopathological Evaluation
All the specimens were formalin fixed and stained 
with hematoxylin and eosin and Elastica-Masson (EM) 
staining. All slides were evaluated by three pathologists 
(NY, SO, and gT) together at a multiheaded microscope and 
discussed until consensus was achieved. The mean number 
of reviewed slides was 2.4 (range, 1–5 slides). Evaluation 
was performed according to the new IASLC/ATS/ERS ADC 
classification,6 each histological component present was 
recorded in 5% increments. The tumors were classified as 
adenocarcinomas in situ (AIS), minimally invasive adeno-
carcinomas (MIA), and invasive ADCs, which were further 
classified into lepidic-predominant, papillary-predominant, 
acinar-predominant, solid-predominant, micropapillary-pre-
dominant, invasive-mucinous ADCs, and others according 
to predominant histological component. The predominant 
pattern was defined as the pattern with the largest percent-
age. In addition, secondary predominant pattern and lepidic 
component rate were also investigated. The amount of lep-
idic growth and assessment of the presence or absence of 
stromal, lymphovascular space, and pleural invasion are the 
important factors in the diagnosis of AIS, MIA, and invasive 
ADCs. To aid in the assessment of the latter features and to 
estimate the amount of lepidic growth present, we evaluated 
the EM staining result in each case wherein a component 
of lepidic growth was present. The study by Sakurai et al.12 
was very useful in our evaluation of the EM staining results, 
as it demonstrated examples of intact elastic frameworks in 
areas of lepidic growth and disrupted elastic frameworks in 
areas of stromal invasion. In line with previous studies,7,8,13 
any area with free-floating tumor cells in alveolar spaces or 
complex branching papillary structures that lacked elastic 
fibers on the EM staining was excluded from the definition 
of lepidic growth. EM staining was also used to determine 
areas of nonlepidic growth, which seemed as solid areas on 
low-power magnification. On high-power magnification of 
the EM stain images, the area of nonlepidic growth usu-
ally showed desmoplastic tumor stroma with surrounding 
bundles of black, broken elastic fibers and an infiltrating 
acinar pattern or less often, an ADC with a papillary pat-
tern, indicative of stromal invasion. Two types of tumor size 
were measured: (1) the total tumor size, and (2) the inva-
sive tumor size based on only the invasive component, not 
including the lepidic growth. The total tumor size was also 
classified as (1) 1 cm or less; (2) more than 1 cm but less 
than or equal to 2 cm; (3) more than 2 cm but less than or 
equal to 3 cm; (4) more than 3cm; the invasive tumor size 
was also classified as (1) 0.5 cm or less; (2) more than 0.5 
cm but less than or equal to 1 cm; 3) more than 1 cm but 
less than or equal to 2 cm; (4) more than 2 cm but less than 
or equal to 3 cm; (5) more than 3 cm. To measure the size 
of the invasive component, the EM staining was helpful. We 
also investigated several histological parameters. Lepidic 
component rate was classified as (1) 0%; (2) 5% or more 
but less than 35%; (3) 35% or more, but less than 70%; 
(4) 70% or more. Visceral pleural invasion was assessed in 
all the cases, using the guidelines of the 7th edition of the 
TNM classification for lung cancer.11 Lymphovascular inva-
sion was also examined.
Statistical Analysis
The statistical comparisons were performed using either 
the χ2 test or Fisher’s exact test or one-factoranalysis of vari-
ance, as appropriate. For patients in this group, disease-free 
survival (DFS) was defined as time from surgery to recur-
rence, lung cancer-related death, or last follow-up. DFS was 
assessed using the Kaplan–Meier method, with a log-rank test 
to probe for significance. Multivariate survival analysis was 
done using Cox proportional hazards model. All statistical 
analyses were performed using Statistical Analysis System 
(SAS) version 9.1 (SAS Institute Inc. Cary, NC).
RESULTS
Frequency of New ADC Classification Patterns
The histopathological assessment according to the new 
ADC classification showed that 5.8% (n = 11) of the cases 
FIGURE 1.  Nonmucinous adeno-
carcinoma in situ. This tumor shows 
growth restricted to the neoplastic 
cells along the preexisting alveolar 
structures (lepidic growth), lacking 
stromal, vascular, or pleural inva-
sion (original magnification: A, ×40; 
B, ×200).
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were AIS (Fig. 1A, B); 8.9% (n = 17), MIA (Fig. 2A–D); 
26.7% (n = 51) were lepidic predominant, 27.2% (n = 52) 
were papillary predominant (Fig. 3A), 20.9% (n = 40) were 
acinar predominant (Fig. 3B), and 10.5% (n = 20) were solid 
predominant (Fig. 3C, Table 1). Micropapillary component 
was seen in four cases, but not predominant. No other histo-
logical subtypes were found.
Patient Characteristics
Patient clinical and histopathological characteristics 
including age, sex, smoking history, surgical procedure, lymph 
node dissection, stage, pleural invasion, lymphovascular 
invasion, secondary predominant pattern, lepidic component 
rate, total tumor size, and invasive tumor size are summarized 
in Table 1 according to ADC classification. In brief, the 
FIGURE 2.  Nonmucinous minimally 
invasive adenocarcinoma. This tumor 
consists primarily of lepidic growth 
but with a small area of invasion. In 
the lower left area is the lepidic pat-
tern, and in the right upper area is 
the invasive area (original magnifica-
tion: A, ×40: B, ×200). The Masson 
elastic staining shows desmoplastic 
tumor stroma, bundles of black, 
broken elastic fiber, and infiltrating 
acinar adenocarcinoma with stromal 
invasion (original magnification: 
C, ×100; D, ×200 Masson elastic 
staining).
FIGURE 3.  Major histopathologic 
patterns of invasive adenocarci-
noma. A papillary adenocarcinoma 
consisting of malignant cuboidal to 
columnar tumor cells growing on 
the surface of the fibrovascular cores 
(original magnification: A, ×200). An 
acinar adenocarcinoma consisting 
of round- to oval-shaped malignant 
glands invading a fibrous stroma 
(original magnification: B, ×200). A 
solid adenocarcinoma with mucin 
consisting of sheets of tumor cells 
with abundant cytoplasm and mostly 
vesicular nuclei with several conspic-
uous nucleoli (original magnification: 
C, ×200).
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median age was 67 years. Of the patients, 51.8% (n = 99) 
were younger than 67 years; 58.1% (n = 111) were women. 
Smokers constituted 40.3% (n = 77) of the patients, and 59% 
(n = 114) were never smokers. Lobectomy was performed 
in 91.6% (n = 175) of the patients. Mediastinal and hilar 
lymph node dissection was performed in 82.2% (n = 157) of 
the patients. Visceral pleural invasion was seen in 18 cases 
(9.4%). Lymphovascular invasion was seen in 20 cases 
(10.5%). Most adenocarcinomas, which excludes AIS, had 
more than two subtypes. As to lepidic component rate, AIS 
was 100%, MIA was 80% (median), and 40% to 90% (range), 
lepidic predominant was 60% (median) and 50% to 90% 
(range), acinar predominant was 10% (median) and 0% to 
30% (range), papillary predominant was 15% (median) and 
0% to 30% (range), and solid predominant was 0% (median) 
and 0% to 10% (range). The total tumor sizes ranged from 0.6 
TABLE 1.  Frequency of New Adenocarcinoma Classification and Correlation with Clinicopathological Backgrounds
Total (%)
AIS MIA Lepidic Acinar Papillary Solid p
11(5.8%) 17(8.9%) 51(26.7%) 40(20.9%) 52(27.2%) 20(10.5%)
Age (yr)
 ≤67 99 (51.8) 5 8 28 20 27 11 0.985a
 >67 92 (48.2) 6 9 23 20 25 9
Sex
 Female 111 (58.1) 8 11 31 26 29 6 0.117a
 Male 80 (41.9) 3 6 20 14 23 14
Smoking history
 No 114 (59.7) 8 12 33 26 30 5 0.031a
 Yes 77 (40.3) 3 5 18 14 22 15
Procedure
 Lobectomy 175 (91.6) 9 15 48 37 48 18 0.955a
 Segmentectomy 16 (8.4) 2 2 3 3 4 2
Lymph node dissection
 Mediastinal and hilar 157 (82.2) 6 13 43 34 45 16 0.203a
 Only hilar 34 (17.8) 5 4 8 6 7 4
TNM stage
 IA 142 (74.3) 11 17 36 31 35 12 0.017a
 IB 49 (25.7) 0 0 15 9 17 8
Visceral pleural invasion
 No 173 (90.6) 11 17 49 33 47 16 0.065a
 Yes 18 (9.4) 0 0 2 7 5 4
Lymphovascular invasion
 No 171 (89.5) 11 17 49 32 47 15 0.015a
 Yes 20 (10.5) 0 0 2 8 5 5
Secondary predominant
 None 11 0 3 1 6 2
 Lepidic 0 0 0 10 26 1
 Acinar 0 5 14 0 18 11
 Papillary 0 12 34 25 0 6
 Solid 0 0 0 4 2 0
Lepidic component rate
 Median% (range) 100 80(50–90) 60(40–100) 10(0–30) 15(0–30) 0(0–10) <0.001b (overall)
 Total tumor size (cm)
 Mean±S.D. 2.2 1.4 ± 0.4 1.8 ± 0.7 2.4 ± 0.8 2.1 ± 0.7 2.4 ± 0.8 2.4 ± 0.8 0.003b (overall)
 Range 0.6–4.5 0.9–2.0 0.8–2.8 1.3–4.3 0.6–3.5 1.0–4.5 1.1–4.3
Invasive tumorsize (cm)
 Mean±S.D. 1.4 0 0.3 ± 0.1 0.9 ± 0.5 1.7 ± 0.7 1.9 ± 0.7 2.3 ± 0.8 <0.001b (overall)
 Range 0–4.3 0 0.1–0.5 0–2.7 0.5–3.5 0.9–4.1 1.1–4.3
a p Value was calculated by χ2 test or Fisher’s exact test. 
b p Value was calculated by one-factor analysis of variance.
AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma: Lepidic, lepidic-predominant;
Acinar, acinar-predominant; Papillary, papillary-predominant; Solid, solid-predominant; SD, standard deviation.
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to 4.5 cm, with a mean size of 2.2 cm, and the invasive tumor 
sizes ranged from 0 to 4.3 cm, with a mean size of 1.4 cm.
Correlation between New ADC Classification 
and Clinicopathological Backgrounds
The frequency of smokers was higher in solid-predomi-
nant than others. Invasive ADCs (lepidic-predominant, acinar-
predominant, papillary-predominant, and solid-predominant) 
were larger than AIS and MIA in total tumor size, however, no 
differences were seen among the four predominant patterns. 
In contrast, invasive tumor sizes were different among inva-
sive ADCs (mean ± SD: lepidic-predominant, 0.9 ± 0.5 cm; 
acinar-predominant, 1.7 ± 0.7 cm; papillary-predominant, 1.9 
± 0.7 cm; solid-predominant, 2.3 ± 0.8 cm).
Survival Analysis
Among the 191 patients, 26 recurred or died of dis-
ease during the study time, seven died of other causes, and 
the remaining patients were alive without evidence of disease 
at the end of the study. The median follow-up time is 61.4 
months (range, 3.5–159.9).
With regard to ADC classification, the 5-year DFS 
of AIS and MIA was 100%; lepidic predominant, 94.9%; 
papillary predominant, 85.4%; acinar predominant, 89.7%; 
solid predominant, 54%. The predominant growth pattern 
was significantly correlated with DFS (p < 0.001, overall) 
(Fig. 4). With regard to tumor size, total tumor size was 
not correlated with DFS (p = 0.475, overall) (Fig. 5A), 
however, invasive tumor size was significantly correlated 
with DFS (≤0.5 cm/ > 0.5cm, ≤1cm/ >1 cm, ≤2 cm/>2 cm, 
≤3 cm/ >3cm, 100%/91.5%/85.9%/80.8%/66.7%% in 5-year 
DFS) (p = 0.006, overall) (Fig. 5B). Lepidic component 
rate was correlated with DFS (0%/≥5%, <35%/≥35%, 
<70%/≥70%, 74.9%/83.4%/91.1%/100% in 5-year DFS) 
(p = 0.003, overall) (Fig. 6). Lymphovascular invasion was 
also correlated with DFS at 5 years (p = 0.005) (Table 2). 
Visceral pleural invasion were slightly associated with DFS 
at 5 years (p = 0.073) (Table 2).
A multivariate analysis adjusting for age, sex, stage, 
new ADC classification, invasive tumor size, pleural inva-
sion, and lymphovascular invasion showed that the new 
ADC classification remained significantly associated with 
DFS in patients of the solid-predominant ADCs having an 
increased risk of recurrence, compared with the patients of 
the nonsolid-predominant (hazard ratio [HR] = 4.08; 95% 
confidence interval [CI]: 1.59–10.5; p = 0.003) ADCs. The 
other independent predictor of increased risk of recurrence 
was invasive tumor size (HR = 2.04; 95% CI: 1.14–3.63; 
p = 0.016) (Table 3).
DISCUSSION
The survival rates of the patients with stage I ADC 
were 73% for stage IA and 58% for stage IB, despite 
FIGURE 4.  DFS of all the patients. The 5-year DFS of AIS 
and MIA was 100%; lepidic-predominant, 94.9%; papillary-
predominant, 85.4%; acinar-predominant, 89.7%; solid-
predominant, 54%. The predominant growth pattern was 
significantly correlated with DFS (p < 0.001, overall). DFS, 
disease-free survival; AIS, adenocarcinoma in situ; MIA, mini-
mally invasive adenocarcinoma.
FIGURE 5. A, Total tumor size was not correlated with DFS (p = 0.475, overall), however, B, invasive tumor size was signifi-
cantly correlated with DFS (≤0.5 cm/ > 0.5cm, ≤1cm/ >1 cm, ≤2 cm/>2 cm, ≤3 cm/ >3cm, 100%/91.5%/85.9%/80.8%/ 
66.7%% in 5-year DFS) (p = 0.006). DFS, disease-free survival.
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complete resection by lymph node dissection.14 Therefore, 
it is important and necessary to identify early-stage patients 
with high risk for recurrence, and this identification will be 
useful to determine more careful follow-up and/or additional 
therapy such as adjuvant therapy. In contrast, for patients 
with no risk or with ultralow risk of recurrence, excessive 
surgery or unnecessary therapy may be avoided. In the pres-
ent study, we have shown a remarkable correlation between 
5-year DFS and the histopathologic subtypes of ADCs on the 
basis of the diagnostic criteria of the new IASLC/ATS/ERS 
international multidisciplinary lung ADC classification.
In our study, the percentage of AIS, MIA, and lepidic-
predominant cases was 41.4% and the rate was higher than 
in previous reports.7,8 However, the 5-year DFS of AIS and 
MIA was 100%; lepidic predominant, 94.9%; papillary 
predominant, 85.4%; acinar predominant, 89.7%; and solid 
predominant, 54%. This result was similar with previous 
report.7 Its report suggested three overall prognostic groups 
with their 5-year DFS rates; these were low grade: AIS and 
MIA (100%); intermediate grade: nonmucinous lepidic-, 
papillary-, and acinar-predominant ADCs (90%, 83%, and 
84%, respectively); and high grade: invasive-mucinous, 
colloid-predominant, solid-predominant, and micropapillary-
predominant ADCs (75%, 71%, 70%, and 67%, respectively). 
Total number of AIS and MIA was larger in our study (n = 
28) than in the study by Yoshizawa et al.7 (n = 9), however 
both results showed 100% of 5-year DFS. These results may 
indicate that patients with AIS and MIA may be nominated 
for limited surgical resection in the future. However, as 
indicated by Yoshizawa et al.7 it can be very difficult for 
a pathologist to exclude invasion on the basis of frozen 
tissue sections, and the role of frozen tissue sections in this 
setting still needs to be defined. In contrast, the multivariate 
analysis showed that the new ADC classification remained 
significantly associated with DFS in patients of the solid-
predominant ADCs having an increased risk of recurrence 
compared with the patients of the nonsolid-predominant 
ADC subtype (HR=4.08; 95%CI: 1.59–10.5; p = 0.003). The 
patients with lepidic-, papillary- and acinar-predominant 
ADCs had an intermediate risk group between AIS+MIA 
and solid-predominant ADCs. It is well known that most 
lung ADCs have more than two subtypes. Therefore, we also 
examined secondary predominant subtype, but secondary 
predominant subtype was not correlated with survival in our 
TABLE 2.  Correlation between Clinicopathological 
Backgrounds and Disease-Free Survival
No. (%) 5-Yr DFS (%) p
Age (yr)
 ≤67 99 (51.8) 86 0.511a
 >67 92 (48.2) 84
Sex
 Female 111 (58.1) 86.9 0.814a
 Male 80 (41.9) 88.3
Smoking history
 No 114 (59.7) 86.8 0.653a
 Yes 77 (40.3) 88.5
TNM stage
 IA 142 (74.3) 87.7 0.522a
 IB 49 (25.7) 86.5
Pleural invasion
 No 173 (90.6) 88.2 0.073a
 Yes 18 (9.4) 81.1
Lymphovascular invasion
 No 171 (89.5) 89 0.005a
 Yes 20 (10.5) 74.4
New ADC classification
 AIS 11 (5.8) 100 <0.001a (overall)
 MIA 17 (8.9) 100
 Lepidic predominant 51 (26.7) 94.9
 Acinar predominant 52 (27.2) 89.7
 Papillary predominant 40 (20.9) 85.4
 Solid predominant 20 (10.5) 54
Total tumor size
 ≤1 cm 12 (6.3) 100 0.475a (overall)
 >1 cm, ≤2 cm 85 (44.5) 85.3
 >2 cm, ≤3 cm 63 (33.0) 86.7
 >3cm 31 (16.2) 90.3
Invasive tumor size
 ≤0.5cm 33 (17.3) 100 0.006a (overall)
 >0.5cm, ≤1 cm 40 (20.9) 91.5
 >1 cm, ≤ 2cm 71 (37.2) 85.9
 >2 cm, ≤3 cm 38 (19.9) 80.8
 > 3cm 9 (4.7) 66.7
Lepidic component rate
 0% (100% invasion) 26 (13.6) 74.9 0.003a (overall)
 ≥5%, ≤35% 76 (39.8) 83.4
 >35%, ≤70% 54 (28.3) 91.1
 >70% 35 (18.3) 100
a p Value was calculated by a log-rank test.
DFS, disease-free survival; ADC, adenocarcinoma; AIS, adenocarcinoma in situ; 
MIA, minimally invasive adenocarcinoma; TNM, tumor, node, metastasis.
FIGURE 6.  Lepidic component rate was correlated with DFS 
(0%/≥5%, <35%/≥35%, <70%/≥70%, 74.9%/83.4%/ 
91.1%/100% in 5-year DFS) (p = 0.003, overall). DFS, 
disease-free survival.
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study. However, the sample number of our study is small 
and further studies will be needed. The new IASLC/ATS/
ERS lung ADC classification is a useful predictor of patient 
survival, independent of the standard established by the 7th 
edition of the TNM staging for lung cancer.
In the new ADC classification, invasive tumor size is 
important because the invasive tumor size separated MIA 
from invasive ADC. Therefore, we measured both total tumor 
size and invasive tumor size. We found that invasive tumor 
size was correlated with DFS, but total tumor size was not 
correlated with DFS. Our result was the same as the previous 
two reports7,9 in terms of correlation between invasive tumor 
size and prognosis, but not in terms of total tumor size. In 
addition, invasive tumor size had an independent predictor of 
increased risk of recurrence (HR =2.04, 95%CI: 1.14–3.63, 
p = 0.016). Lepidic component rate was also correlated with 
survival, and we think there is a close relationship between 
invasive tumor size and lepidic component rate. Although 
more additional studies will be needed, measuring of invasive 
tumor size, instead of total tumor size, might become the 
standard in the near future.
In conclusion, the new IASLC/ATS/ERS ADC clas-
sification and invasive tumor size are very useful predictors 
of recurrence of patients with stage I lung ADC, and a more 
robust prospective study should be performed to validate the 
efficacy of these predictors.
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TABLE 3.  Multivariate Survival Analysis for Disease-Free 
Survival
Variable HR (95%CI) p
New ADC classification (solid vs. nonsolid) 4.08 (1.59–10.5) 0.003
Tumor size (invasion) 2.04 (1.14–3.63) 0.016
Age (yr) 1.02 (0.97–1.08) 0.441
Sex (female vs. male) 0.67 (0.28–1.63) 0.38
Stage (IA vs. IB) 0.34 (0.08–1.41) 0.139
Pleural invasion (yes vs. no) 3.26 (0.68–15.6) 0.14
Lymphovascular invasion (yes vs. no) 2.29 (0.78–6.74) 0.134
HR, hazards ratio; CI, confidence interval; ADC, adenocarcinoma.
